Regeneron Pharmaceuticals REGN Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's total liabilities & equity?
- Regeneron Pharmaceuticals (REGN) reported total liabilities & equity of $40.87B in Q1 2026.
- How has Regeneron Pharmaceuticals's total liabilities & equity changed year-over-year?
- Regeneron Pharmaceuticals's total liabilities & equity increased by 8.9% year-over-year, from $37.55B to $40.87B.
- What is the long-term trend for Regeneron Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total liabilities & equity has grown at a 18.8% compound annual growth rate (CAGR), from $17.16B to $40.56B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.